Patterns of genetic alterations in pancreatic cancer: A pooled analysis

Environmental and Molecular Mutagenesis

Volumn 33, Issue 2, 1999, Pages 111-122

  Blanck, Heidi Michels ^a   Tolbert, Paige E ^b   Hoppin, Jane A ^b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Epidemiology; Gene mutations; P53, K ras; Pancreatic cancer

Indexed keywords

PROTEIN P53;

ARTICLE; BLADDER CANCER; CANCER GENETICS; CANCER GRADING; CIGARETTE SMOKING; CORRELATION FUNCTION; GENE FREQUENCY; GENE POOL; HUMAN; HUMAN CELL; ONCOGENE K RAS; PANCREAS CANCER; POINT MUTATION;

ADENOCARCINOMA; GENES, P53; GENES, RAS; HUMANS; MUTATION; PANCREATIC NEOPLASMS;

EID: 0032939249     PISSN: 08936692     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2280(1999)33:2<111::AID-EM3>3.0.CO;2-F     Document Type: Article

References (42)

1. American Cancer Society. 1998. Cancer facts and figures. 1998. Atlanta, GA: American Cancer Society.
2. th ed. Philadelphia: J.B. Lippincott.
3. Berozzpe G, Schaeffer J, Peinado MA, Real FX, Perucho M. 1994. Comparative analysis of mutations in the p53 gene and K-ras genes in pancreatic cancer. Int J Cancer 58:185-191.
4. Caldas C, Kern SE. 1995. K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol 18:1-6.
5. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruhan RH, Yeo CJ, Kern SE. 1994. Frequent somatic mutations and homozygous deletions of the p16(MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27-32.
6. Condie A, Eeles R, Borresen AL, Coles C, Cooper C, Prosser J. 1993. Detection of point mutations in the p53 gene: comparison of single-strand conformation polymorphism, constant denaturant gel electrophoresis, and hydroylamine and osmium tetroxide techniques. Hum Mutat 2:56-66.
7. Dergham ST, Dugan MC, Arlauskas P, Du W, Vaitkevicius VK, Crissman JD, Sarkar FH. 1997. Relationship of family cancer history to the expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma. Int J Pancreatol 21(3):225-234.
8. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356(6366):215-221.
9. Esteve A, Sorlie T, Maertel-Plance G, Hollstein M, Kusters I, Lewalter J, Vineis P, Stephan-Odenthal M, Montesano R. 1995. Screening for p53 gene mutations in archived tumors of workers exposed to carcinogens: examples from analysis of bladder tumors. J Occup Environ Med 37:59-68.
10. Flanders TY, Foulkes WD. 1996. Pancreatic adenocarcinoma: epidemiology and genetics. J Med Genet 33:889-898.
11. Friess H, Berberat P, Schilling M, Kunz J, Korc M, Buchler MW. 1996. Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J Mol Med 74:35-42.
12. Gold EB, Goldin SB. 1998. Epidemiology of and risk factor for pancreatic cancer. Surg Oncol Clin N Am 7(1):67-91.
13. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878.
14. Grompe M. 1993. The rapid detection of unknown mutations in nucleic acids. Nat Genet 5:111-117.
15. Grunewald K, Lyons J, Frohlich A, Feichtinger H, Weger RA, Schwab G, Janssen JWG, Bartram CR. 1989. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 43:1037-1041.
16. Hansen R, Oren M. 1997. p53: from inductive signal to cellular effect. Curr Opin Genet Dev 7:46-51.
17. Harris CC. 1996. P53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. Environ Health Perspect 104:435-439.
18. Hollstein M, Sidransky D, Vogelstein B, Harris C. 1991. p53 mutations in human cancers. Science 253:49-53.
19. Hoshi T, Imai M, Ogawa K. 1994. Frequent K-ras mutations and absence of p53 mutations in mucin-producing tumors of the pancreas. J Surg Oncol 55:84-91.
20. Lemoine NR, Jain S, Hughes C, Staddon S, Maillet B, Hall P, Kloppel G. 1992. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 102:230-236.
21. Levine AJ. 1997. P53, the cellular gatekeeper for growth and division. Cell 88:323-331.
22. Kaino M. 1997. Alterations in the tumor suppressor genes p53, RB, p16/MTS1, and p15/MTS2 in human pancreatic cancer and hepatoma cell lines. J Gastroenterol 32:40-46.
23. Kloppel G. 1984. Pancreatic, non-endocrine tumors. In: Kloppel G, Heitz PU, editors. Pancreatic pathology. Edinburgh: Churchill Livingstone, p 79-113.
24. McCormick F. 1995. Ras-related proteins in signal transduction and growth control. Mol Reprod Dev 42:500-506.
25. Nagata Y, Abe M, Motoshima K, Nakayma E, Shiku H. 1990. Frequent glycine-to-aspartic acid mutations at codon 12 of c-Ki-ras gene in human pancreatic cancer (in Japanese). Jpn J Cancer Res 81:135-140.
26. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, Ranzani GN. 1994. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 54:1556-1560.
27. Rall CJN, Van YX, Graeme-Cook F, Beauchamp R, Yandell DW, Povoskli SP, Rustgi AK. 1996. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma. Pancreas 12:10-17.
28. Redston MS, Caldas C, Seymour CB, Hruban RH, da Costa L, Yeo CJ, Kern SE. 1994. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 54:3025-3033.
29. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE. 1997. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 57:1731-1734.
30. Ruggeri B, Zhang S-Y, Caamano J, DiRado M, Flynn SD, Klein-Szanto AJP. 1992. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 7:1503-1511.
31. Ruggeri BA, Huang L, Berger D, Chang H, Kjlein-Szanto AJ, Goodrow T, Obara T, Heath CW, Lynch H. 1997. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Cancer 79:700-716.
32. th ed. Cary, NC: SAS Institute.
33. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacona C, Hiohashi S. 1993. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 142:1534-1542.
34. Scarpa A, Capelli P, Villaneuva A, Zamboni G, Lluis F, Accolla R, Mariuzzi G, Capella G. 1994. Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences. Int J Cancer 57:167-171.
35. Smit THBM, Boot AJM, Smits AMM, Fleuren GJ, Cornelisse CJ, Bos JL. 1988. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 16:7773-7782.
36. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. 1994. Multifactorial analysis of p53 alterations in human cancer: a review. Int J Cancer 57:1-9.
37. th ed. College Station, TX: Stata Corp.
38. Tada M, Ohashi M, Shiratori Y, Okudaira T, Komatsu Y, Kawabe T, Yoshida H, Machinami R, Kishi K, Omata M. 1996. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 100:227-231.
39. Taylor WR, Eagan SE, Mowat M, Greenberger AH, Wright JA. 1992. Evidence for synergistic interactions between ras, myc, and a mutant form of p53 in cellular transformation and tumor dissemination. Oncogene 7:1383-1390.
40. Terhune PG, Phifer DM, Tosteson TD, Longnecker DS. 1998. K-ras mutation in focal proliferative lesions of human pancreas. Cancer Epidemiol Biomarkers Prev 7:515-521.
41. Weyrer K, Feichtinger H, Haun M, Weiss G, Ofner D, Weger AR, Umlauft F, Grunewald K. 1996. P53, Ki-ras, and DNA ploidy in pancreatic adenocarcinomas. Lab Invest 74:279-289.
42. Yanagisawa K, Ohtake K, Ohashi K, Hori M, Kitagawa T, Sugano H, Kato Y. 1993. C-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 53: 953-956.